Phase 2 N=54 Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA)
Lymphedema
Primary: Change in Skin Thickness of the Calf of the Most Affected Leg, Measured by Skinfold Calipers — -6.83; -7.75 mm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=447 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
Cystic Fibrosis
Primary: Pulmonary Exacerbation (PEx) Rate Over 28 Weeks — 0.911; 0.749; 0.842 events per participant/28 weeks
Phase 2 N=33 A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection
Hepatitis D, Chronic
Primary: Change From Baseline in HDV Viral Load. — -2.14; -1.16 Change in HDV RNA log IU/mL
Phase 2 N=123 Open-label Extension to Protocol 1042-0600
Epilepsies, Partial
Primary: Percent Change From Baseline in Weekly Seizure Frequency During Weeks 1 Through 117 — -14.8; -12.3; -14.0; -13.7 Percent Change
Phase 2 N=140 Trial of AD036 in Obstructive Sleep Apnea
Obstructive Sleep Apnea
Primary: Apnea Hypopnea Index (AHI) — 3; 2; 6; 8 Participants
Phase 2 N=233 Biopsychosocial Influence on Shoulder Pain
Shoulder Pain
Primary: Number of Participants Who Met the Recovery Criterion for Shoulder Pain Intensity — 39; 32; 32; 32 Participants
Phase 2 N=13 Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder
Primary: Pharmacokinetic (PK) Parameter: Maximum Plasma Concentration (Cmax) of Centanafadine — 153; 129 nanograms per milliliter (ng/mL)
Phase 2 N=44 Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Morphine
Healthy
Primary: Tolerance to Simulated Hemorrhage — 385; 692 CSI: Cumulative Stress Index
Phase 2 N=124 High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients
Hematopoietic Cell Transplantation
Primary: HD-TIV Compared With SD-QIV (Influenza A) - Immunogenicity — 0.62; 0.59; 0.23; 0.25 proportion of participants
Phase 2 N=93 Efficacy and Safety of VDA-1102 Ointment in the Treatment of Actinic Keratosis
Actinic Keratosis
Primary: Change From Baseline in the Number of Actinic Keratosis Lesions in the Treatment Field on Day 56 — -1.54; -1.34; -1.94 lesions — p=0.9518
Phase 2 N=32 Effects of Metformin in a Non-Diabetic Patient Population
Inflammatory Response
Primary: Ex Vivo Cytokine Response of Peripheral Blood Mononucleocytes (PBMC) to Inflammatory Stimuli Compared to Baseline, Throughout Exposure, and Following Exposure to…
Phase 2 N=114 Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)
Hypertriglyceridemia · Cardiovascular Diseases
Primary: Percent Change From Baseline in Fasting Triglycerides (TG) at the Primary Analysis Time Point — 6; -23; -56; -60 percent change — p=0.0042
Phase 2 N=12 [68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Number of Patients Demonstrating Somatostatin Receptor Positivity in Hepatocellular Carcinoma Using [68Ga]DOTATATE-PET — 0 Participants
Phase 2 N=26 Trial of Nicotinamide Riboside and Co-enzyme Q10 in Chronic Kidney Disease
Chronic Kidney Disease · Sarcopenia · Frailty
Primary: Maximal Aerobic Capacity- CoQ10 — 21.4; 20.7; 20.7 mL/min/kg — p=0.33
Phase 2 N=140 Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Metastatic Melanoma · Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor · Recurrent Hodgkin Lymphoma
Primary: Frequency of Dose Limiting Toxicities of Nivolumab as a Single Agent or in Combination With Ipilimumab — 0; 0; 5; 0 Participants